Strategic Acquisition Focus IBA Dosimetry actively enhances its product portfolio and market reach through strategic acquisitions, such as Radcal and Modus Medical Devices. These acquisitions suggest opportunities for cross-selling high-end QA and imaging solutions to a broader customer base, including radiology and radiation therapy providers.

Innovative Product Launches The company has launched advanced integrated QA platforms like myQA iON and software environments such as myQA Machines 2019. These technological innovations present opportunities to upsell updated or complementary diagnostic and therapy calibration solutions in hospitals and clinics.

Global Presence Expansion With subsidiaries in the US and China and recent acquisitions strengthening its North American footprint, there are potential sales opportunities in expanding into these growing markets with localized marketing of its dosimetry and QA solutions tailored to regional healthcare systems.

Adaptation to Market Trends As healthcare providers aim for increased precision in radiation diagnostics and therapy, IBA Dosimetry’s focus on safety and accuracy aligns well with customer needs for reliable QA solutions, highlighting prospects for demonstrating product value to institutions prioritizing patient safety and treatment efficacy.

Mid-Range Revenue Potential With revenues estimated between 1M and 10M, the company offers opportunities to penetrate mid-sized hospitals and radiotherapy centers that seek high-tech, scalable QA solutions, providing a solid entry point for expanding their customer base in the medical equipment market.